Michael Barbella, Managing Editor05.09.23
One thousand U.S. patients have been treated with OssDsign AB's nanosynthetic bone graft OssDsign Catalyst, the company announced Tuesday.
Product awareness is increasing considerably, as OssDsign reached a 500-patient milestone in January and doubled that number in four months. The company launched OssDsign Catalyst in August 2021.
“OssDsign Catalyst is growing exponentially driven by a continuously growing customer base as well as broader usage within the hospitals and, in the last four months alone, we have doubled the number of patients treated. This is an outstanding development that highlights the potential for OssDsign Catalyst to become the preferred product for spinal fusion surgeries,” OssDsign CEO Morten Henneveld said.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates healthy bone tissue formation in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure that is resorbed and replaced by new and healthy bone tissue. The U.S. market clearance is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion, the Boden model. OssDsign continues to accelerate a program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry, and the clinical study TOP FUSION, in which patient enrolment was completed in April 2022.
OssDsign develops and provides next-generation bone replacement products. Based on cutting-edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, the company has a strong commercial presence in the United States, Europe, and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Product awareness is increasing considerably, as OssDsign reached a 500-patient milestone in January and doubled that number in four months. The company launched OssDsign Catalyst in August 2021.
“OssDsign Catalyst is growing exponentially driven by a continuously growing customer base as well as broader usage within the hospitals and, in the last four months alone, we have doubled the number of patients treated. This is an outstanding development that highlights the potential for OssDsign Catalyst to become the preferred product for spinal fusion surgeries,” OssDsign CEO Morten Henneveld said.
OssDsign Catalyst is a nanosynthetic bone graft that stimulates healthy bone tissue formation in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure that is resorbed and replaced by new and healthy bone tissue. The U.S. market clearance is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion, the Boden model. OssDsign continues to accelerate a program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry, and the clinical study TOP FUSION, in which patient enrolment was completed in April 2022.
OssDsign develops and provides next-generation bone replacement products. Based on cutting-edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, the company has a strong commercial presence in the United States, Europe, and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.